- Tenax Therapeutics (TENX) is down ~89% after announcing that TNX-103 (oral levosimendan) failed to meet its primary goal in a phase 3 trial for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
- There was no improvement difference
